Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis
- PMID: 18184959
- PMCID: PMC3398441
- DOI: 10.1056/NEJMoa063564
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis
Abstract
Background: Angiomyolipomas in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis genes resulting in constitutive activation of the mammalian target of rapamycin (mTOR). The drug sirolimus suppresses mTOR signaling.
Methods: We conducted a 24-month, nonrandomized, open-label trial to determine whether sirolimus reduces the angiomyolipoma volume in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. Sirolimus was administered for the first 12 months only. Serial magnetic resonance imaging of angiomyolipomas and brain lesions, computed tomography of lung cysts, and pulmonary-function tests were performed.
Results: Of the 25 patients enrolled, 20 completed the 12-month evaluation, and 18 completed the 24-month evaluation. The mean (+/-SD) angiomyolipoma volume at 12 months was 53.2+/-26.6% of the baseline value (P<0.001) and at 24 months was 85.9+/-28.5% of the baseline value (P=0.005). At 24 months, five patients had a persistent reduction in the angiomyolipoma volume of 30% or more. During the period of sirolimus therapy, among patients with lymphangioleiomyomatosis, the mean forced expiratory volume in 1 second (FEV1) increased by 118+/-330 ml (P=0.06), the forced vital capacity (FVC) increased by 390+/-570 ml (P<0.001), and the residual volume decreased by 439+/-493 ml (P=0.02), as compared with baseline values. One year after sirolimus was discontinued, the FEV1 was 62+/-411 ml above the baseline value, the FVC was 346+/-712 ml above the baseline value, and the residual volume was 333+/-570 ml below the baseline value; cerebral lesions were unchanged. Five patients had six serious adverse events while receiving sirolimus, including diarrhea, pyelonephritis, stomatitis, and respiratory infections.
Conclusions: Angiomyolipomas regressed somewhat during sirolimus therapy but tended to increase in volume after the therapy was stopped. Some patients with lymphangioleiomyomatosis had improvement in spirometric measurements and gas trapping that persisted after treatment. Suppression of mTOR signaling might constitute an ameliorative treatment in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. (ClinicalTrials.gov number, NCT00457808.)
2008 Massachusetts Medical Society
Conflict of interest statement
No other potential conflict of interest relevant to this article was reported.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3398441/bin/nihms116421f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3398441/bin/nihms116421f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3398441/bin/nihms116421f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3398441/bin/nihms116421f4.gif)
Comment in
-
Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis.N Engl J Med. 2008 Jan 10;358(2):190-2. doi: 10.1056/NEJMe0707153. N Engl J Med. 2008. PMID: 18184966 No abstract available.
-
Sirolimus for lymphangioleiomyomatosis lesions.N Engl J Med. 2008 May 1;358(18):1963-4; author reply 1964. doi: 10.1056/NEJMc086040. N Engl J Med. 2008. PMID: 18450609 No abstract available.
Similar articles
-
Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.N Engl J Med. 2008 Jan 10;358(2):200-3. doi: 10.1056/NEJMc072500. N Engl J Med. 2008. PMID: 18184971 No abstract available.
-
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.Clin Cancer Res. 2011 Jun 15;17(12):4071-81. doi: 10.1158/1078-0432.CCR-11-0445. Epub 2011 Apr 27. Clin Cancer Res. 2011. PMID: 21525172 Clinical Trial.
-
Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.Orphanet J Rare Dis. 2018 Mar 27;13(1):43. doi: 10.1186/s13023-018-0781-y. Orphanet J Rare Dis. 2018. PMID: 29587809 Free PMC article. Clinical Trial.
-
Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.J Urol. 2014 Nov;192(5):1424-30. doi: 10.1016/j.juro.2014.04.096. Epub 2014 May 9. J Urol. 2014. PMID: 24813310 Review.
-
Lymphangioleiomyomatosis.Clin Chest Med. 2016 Sep;37(3):389-403. doi: 10.1016/j.ccm.2016.04.002. Clin Chest Med. 2016. PMID: 27514586 Review.
Cited by
-
Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis.Orphanet J Rare Dis. 2024 Aug 15;19(1):299. doi: 10.1186/s13023-024-03243-5. Orphanet J Rare Dis. 2024. PMID: 39148107 Free PMC article.
-
Loss of Tuberous Sclerosis Complex 2 confers inflammation via dysregulation of Nuclear factor kappa-light-chain-enhancer of activated B cells.Res Sq [Preprint]. 2024 Jul 15:rs.3.rs-4569999. doi: 10.21203/rs.3.rs-4569999/v1. Res Sq. 2024. PMID: 39070657 Free PMC article. Preprint.
-
Kidney transplantation in patients with tuberous sclerosis complex.Pediatr Transplant. 2024 Jun;28(4):e14765. doi: 10.1111/petr.14765. Pediatr Transplant. 2024. PMID: 38778713
-
Carbonic Anhydrase 2 Deletion Delays the Growth of Kidney Cysts Whereas Foxi1 Deletion Completely Abrogates Cystogenesis in TSC.Int J Mol Sci. 2024 Apr 27;25(9):4772. doi: 10.3390/ijms25094772. Int J Mol Sci. 2024. PMID: 38731991 Free PMC article.
-
Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.Arch Gynecol Obstet. 2024 Jun;309(6):2381-2386. doi: 10.1007/s00404-024-07510-5. Epub 2024 Apr 25. Arch Gynecol Obstet. 2024. PMID: 38664269 Free PMC article. Review.
References
-
- Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol. 2004;19:643–9. - PubMed
-
- Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int. 2004;66:924–34. - PubMed
-
- Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001;164:661–8. - PubMed
-
- Karbowniczek M, Astrindis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003;167:976–82. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous